A detailed history of Federated Hermes, Inc. transactions in Mannkind Corp stock. As of the latest transaction made, Federated Hermes, Inc. holds 1,904,281 shares of MNKD stock, worth $13.4 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,904,281
Previous 1,883 101030.16%
Holding current value
$13.4 Million
Previous $9,000 132766.67%
% of portfolio
0.03%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.01 - $6.7 $9.53 Million - $12.7 Million
1,902,398 Added 101030.16%
1,904,281 $12 Million
Q2 2024

Aug 08, 2024

BUY
$4.05 - $5.43 $5,200 - $6,972
1,284 Added 214.36%
1,883 $9,000
Q1 2024

May 14, 2024

BUY
$3.25 - $5.27 $1,946 - $3,156
599 New
599 $2,000
Q4 2022

Feb 13, 2023

BUY
$3.02 - $5.37 $211 - $375
70 Added 7000.0%
71 $0
Q3 2022

Nov 14, 2022

BUY
$2.99 - $4.35 $2 - $4
1 New
1 $1,000
Q2 2022

Aug 15, 2022

SELL
$2.67 - $4.77 $5 - $9
-2 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$2.62 - $4.45 $266,831 - $453,205
-101,844 Reduced 100.0%
2 $1,000
Q4 2021

Feb 14, 2022

SELL
$4.05 - $5.37 $388 - $515
-96 Reduced 0.09%
101,846 $445,000
Q3 2021

Nov 15, 2021

BUY
$3.89 - $5.48 $373 - $526
96 Added 0.09%
101,942 $443,000
Q2 2021

Aug 16, 2021

SELL
$3.61 - $5.45 $445,376 - $672,382
-123,373 Reduced 54.78%
101,846 $555,000
Q1 2021

May 13, 2021

BUY
$3.14 - $6.14 $404,444 - $790,856
128,804 Added 133.59%
225,219 $883,000
Q4 2020

Feb 12, 2021

BUY
$1.79 - $4.04 $171,426 - $386,906
95,769 Added 14824.92%
96,415 $302,000
Q2 2020

Aug 13, 2020

BUY
$0.94 - $2.21 $607 - $1,427
646 New
646 $1,000
Q2 2019

Aug 14, 2019

SELL
$1.09 - $1.88 $1,468 - $2,532
-1,347 Closed
0 $0
Q1 2019

May 10, 2019

BUY
$1.14 - $2.25 $1,535 - $3,030
1,347 New
1,347 $3,000

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.81B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.